Published in Vasc Health Risk Manag on June 08, 2011
Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats. PLoS One (2013) 0.95
Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. J Am Heart Assoc (2017) 0.75
Genomic and rapid effects of aldosterone: what we know and do not know thus far. Heart Fail Rev (2016) 0.75
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Inositol trisphosphate and calcium signalling. Nature (1993) 25.57
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev (1993) 4.69
Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet (2001) 4.65
Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation (1990) 2.89
Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med (1992) 2.54
Aldosterone in congestive heart failure. N Engl J Med (2001) 2.46
Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J (2008) 2.37
A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol (2008) 1.85
Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension (2002) 1.81
Hormones and the pathogenesis of congestive heart failure: vasopressin, aldosterone, and angiotensin II. Further evidence for renal-adrenal interaction from studies in hypertension and in cirrhosis. Circulation (1962) 1.66
Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis (2003) 1.59
Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts. Hypertension (2005) 1.53
Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol (1993) 1.49
Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest (1994) 1.48
SPLANCHNIC EXTRACTION AND CLEARANCE OF ALDOSTERONE IN SUBJECTS WITH MINIMAL AND MARKED CARDIAC DYSFUNCTION. J Clin Endocrinol Metab (1965) 1.40
Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol (2008) 1.36
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens (2002) 1.36
Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res (1997) 1.31
Aldosterone and potassium homeostasis. Kidney Int (1996) 1.28
Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol (2001) 1.23
Disorders of aldosterone biosynthesis and action. N Engl J Med (1994) 1.21
Potassim-aldosterone-renin interrelationships. J Clin Endocrinol Metab (1975) 1.20
Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res (2005) 1.19
Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation (2001) 1.19
Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension (1992) 1.17
Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail (2010) 1.15
Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation (2004) 1.12
Aldosterone in fluid and electrolyte disorders: hyper- and hypoaldosteronism. J Chronic Dis (1960) 1.09
Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension (1999) 1.08
Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol (1987) 1.08
Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther (1973) 1.05
Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res (2007) 1.01
Eplerenone: cardiovascular protection. Circulation (2003) 0.99
Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int (1991) 0.98
Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol (2005) 0.98
Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension (1995) 0.95
Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail (2009) 0.95
Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens (1999) 0.95
Potassium-sparing diuretics. Ren Physiol (1987) 0.94
Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol (1989) 0.94
Nongenomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension (2005) 0.91
New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther (1985) 0.86
Sodium-dependent modulation of the renal Na-K-ATPase: influence of mineralocorticoids on the cortical collecting duct. J Membr Biol (1985) 0.85
Aldosterone and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes (2010) 0.84
Multiplicative interaction between angiotensin II and K concentration in stimulation of aldosterone. Am J Physiol (1984) 0.83
The cellular action of aldosterone in target epithelia. Kidney Int (1992) 0.83
Atrial natriuretic peptide-induced inhibition of aldosterone secretion: a quest for mediator(s) Am J Physiol (1992) 0.79
Aldosterone and cardiovascular risk. Curr Hypertens Rep (2009) 0.79
Production of renin, angiotensin II, and aldosterone by adrenal explant cultures: response to potassium and converting enzyme inhibition. Endocrinology (1989) 0.78
Elimination of canrenone in congestive heart failure and chronic liver disease. Eur J Clin Pharmacol (1977) 0.77
Renin release from microdissected superficial, midcortical, and juxtamedullary afferent arterioles in rabbits. Kidney Int (1990) 0.76
Eplerenone in mild heart failure. N Engl J Med (2011) 0.76
Eplerenone in mild heart failure. N Engl J Med (2011) 0.76
Pharmacokinetics of spironolactone in man. Naunyn Schmiedebergs Arch Pharmacol (1976) 0.76
Improved ticagrelor antiplatelet effect on discontinuation of phenytoin. Ann Pharmacother (2014) 0.75